Origin, sequence, and stability
BPC-157 is a fifteen–amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a fragment of a larger "body protection compound" identified in the aqueous phase of human gastric juice. The proline-rich core is thought to contribute to the peptide's notable stability in aqueous solution — a property that distinguishes it from many short peptides that require acidic or organic conditions to remain intact.
In practical research terms, BPC-157 is stable enough in dilute aqueous solution to allow routine handling in laboratory experiments without solvent gymnastics. That behaviour is one reason it became a common tool compound in preclinical repair studies.
The Zagreb preclinical program
The bulk of the BPC-157 literature originates from a research program led for many years by Sikiric and colleagues at the University of Zagreb. The group's publications span gastroprotection, tendon and ligament repair, muscle injury, vascular models, and — more recently — brain-injury and gut–brain-axis models.
The concentration of publications from a single program is worth flagging when reading the literature: it is a strength (deep, methodical characterisation in a consistent model system) and also a call for independent replication from other groups, several of which have contributed confirming and extending studies.
Gastrointestinal research
The earliest BPC-157 studies focused on cytoprotection in the gastrointestinal tract. Preclinical models included stress-induced gastric lesions, ethanol-induced gastric injury, and models of colitis and inflammatory bowel injury. Reported endpoints in the animal literature include reductions in lesion area, faster mucosal restoration, and modulation of nitric oxide pathway activity in the mucosa.
The gastrointestinal work established the framework used in later studies: an injury or challenge model, a defined observation window, and morphological plus biochemical readouts.
Musculoskeletal repair research
A second wave of research extended BPC-157 study to musculoskeletal injury. The most-cited models involve rat Achilles tendon transection and medial collateral ligament transection, with tendon-to-bone healing and functional recovery followed over a period of weeks.
Cell-based work has reported effects on tendon fibroblast (tendocyte) outgrowth and migration in culture, giving the tendon-repair literature a mechanistic complement to the animal-model endpoints. Muscle-transection and crush models expanded the picture to skeletal muscle repair.
Angiogenesis and vascular research
A recurring theme across the BPC-157 literature is angiogenic activity — the formation of new blood vessels — and interaction with vascular pathways including the VEGF axis and nitric-oxide (NO) system. This has been proposed as a common thread linking the disparate injury models: many tissues heal better when perfusion is preserved and new microvasculature is recruited.
Angiogenesis endpoints have been assessed in chick chorioallantoic membrane assays, tube-formation assays in cultured endothelial cells, and vessel-density counts in tissue sections from injury models.
Central nervous system and gut–brain axis research
A more recent extension of the BPC-157 literature has looked at central nervous system and gut–brain axis endpoints. Preclinical models in this line of work include rodent brain-injury models (traumatic and hypoxic), stroke-model variants, and studies of behavioural or physiological endpoints downstream of enteric or vagal signalling. The Zagreb group's later synthesis papers frame BPC-157 within a broader concept they label "cytoprotection / organoprotection" — a proposed unifying mechanism spanning gastric mucosa, tendon, vasculature, and CNS injury contexts.
The mechanistic thread most commonly proposed to link these endpoints is engagement of the nitric-oxide (NO) system. BPC-157 has been reported to modulate the NO pathway in a context-dependent manner — attenuating over-activation in some models and restoring signalling in others. Because NO signalling is present across gut, vascular, and CNS tissues, that mechanism would rationalise the breadth of preclinical endpoints without requiring a separate receptor at each site.
The evidence for a specific receptor for BPC-157 is not yet established in the published literature. That is a notable gap: most tissue-repair peptides in this class have at least a candidate receptor characterised, and the absence of one for BPC-157 shapes how mechanistic claims should be read. Reports of downstream effects on VEGF, growth-factor signalling, and cytokine profiles are extensive; the direct receptor engagement upstream is what remains under-characterised.
For research purposes, this literature is useful context both for framing new experiments and for calibrating expectations of what the preclinical evidence base does and does not yet support. Broad activity across multiple systems is one of the reasons BPC-157 has attracted attention; it is also a reason to design comparative studies that can isolate the pathway a specific observation is being attributed to.
Comparative context: BPC-157, TB-500, and GHK-Cu
In the tissue-repair peptide literature, BPC-157 is most often mentioned alongside TB-500 (a synthetic fragment corresponding to Thymosin β-4's actin-binding domain) and the copper tripeptide GHK-Cu. All three are studied in wound-healing and repair models but arrive at those endpoints through distinct proposed mechanisms — TB-500 through actin sequestration and endothelial cell recruitment, GHK-Cu through copper delivery and matrix signalling, and BPC-157 through the mixed cytoprotective and angiogenic activities outlined above.
Head-to-head comparative preclinical studies are limited; most of what is written about relative activity is inferred from parallel published work. This is a common gap in the literature and one worth being explicit about when framing research.
Analytical characterisation
Identity and purity of BPC-157 are typically confirmed by liquid-chromatography–mass spectrometry (LC-MS) for identity and reversed-phase HPLC for purity. The theoretical monoisotopic mass of the free-acid form is approximately 1419.5 Da; small deviations arise from counter-ions and residual water in lyophilised material.
Because the peptide is proline-rich, HPLC methods that resolve close-eluting proline-containing impurities are informative when characterising a lot. A batch certificate of analysis should show a dominant single peak and the mass-spec identity confirmation for the correct molecular weight.
Worked examples
Reconstituting a 5 mg BPC-157 vial
- 01Bring the sealed vial to room temperature before opening — this reduces condensation on the stopper and inside the vial.
- 02Wipe the stopper with an alcohol swab. Draw the chosen volume of bacteriostatic water into a syringe — 2.5 mL is a common choice, yielding a 2 mg/mL working concentration.
- 03Insert the needle through the stopper and let the diluent run down the inside wall of the vial. Do not spray directly onto the powder.
- 04Swirl gently to dissolve. Do not shake. If material remains, allow additional time at room temperature.
- 05Record the lot number, diluent, volume added, resulting concentration, and date on the vial and in the lab notebook.
Storage protocol for a multi-week research timeline
- 01Lyophilised material: keep sealed and desiccated at 2–8 °C for short-term or −20 °C for longer-term storage.
- 02After reconstitution: refrigerate and aliquot into single-use portions to minimise repeated freeze-thaw exposure.
- 03Label every aliquot with lot, concentration, and reconstitution date. Freeze-thaw cycles are the largest avoidable source of variability across a study timeline.
Frequently asked questions
What does BPC stand for?
BPC stands for Body Protection Compound — the name given to the larger gastric-juice protein from which the 15-amino-acid BPC-157 sequence was derived.
Is BPC-157 a naturally occurring peptide?
The full sequence is not itself synthesised as a discrete natural peptide; it is a fragment of a larger endogenous protein present in gastric juice. Research-grade BPC-157 is chemically synthesised.
What preclinical models has BPC-157 been studied in?
Published preclinical models span gastric and intestinal injury, Achilles tendon transection, ligament injury, muscle transection, brain-injury models, and various vascular and angiogenesis assays — spread across rodent studies and cell-based systems.
What analytical tests confirm identity and purity?
Reversed-phase HPLC is used for purity determination and LC-MS or MALDI-MS is used for identity confirmation against the expected molecular weight. A lot certificate of analysis should include both.
How should lyophilised BPC-157 be stored?
Sealed and desiccated at 2–8 °C for short-term or −20 °C for longer-term storage, away from light. After reconstitution, refrigerate and aliquot to minimise freeze-thaw cycles.
References
Selected published research referenced in this article.
- 01Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. PubMed
- 02Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PubMed
- 03Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982–989. PubMed
- 04Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PubMed
- 05Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157's effect on healing. J Physiol Paris. 1997;91(3–5):173–178. PubMed
- 06Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response: progress, achievements, and the future. Gut Liver. 2020;14(2):153–167. PubMed